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RESEARCH ARTICLE
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In potentially inherited cardiac diseases, the family history is
of great importance. We looked at the way cardiologists take a
family history in patients with idiopathic dilated cardiomyopa-
thy (DCM) or long QT syndrome (LQTS) and whether this led to
screening of relatives or other follow-up. We performed retro-
spective cross-sectional analyses of adult index patients with
DCM or LQTS in a general hospital (GH) or a University Medical
Center (UMC). We identified 82 index patients with DCM
(34 GH; 48 UMC) and 20 with LQTS (all UMC) between 1996
and 2005. Mean follow-up was 58 months. A family history was
recorded in 90% of both LQTS and DCM patients most of the
cases restricted to first-degree family members. The genetic
aspects, counseling and screening of family members was dis-
cussed significantly more often with LQTS than DCM patients
(all P< 0.05). Also follow-up (screening of family members,
DNA analysis and referral) was performed significantly more
often in LQTS than DCM patients. Cardiologists in the UMC
referred DCM index patients for genetic counseling more often
than those in the GH (25% vs. 6%; P< 0.05). Only a few index
patients with DCM were referred to a clinical genetics depart-
ment. One-third of DCM cases and nearly all LQTS cases are
familial. Since early recognition and treatment may reduce
morbidity and mortality we recommend cardiologists take a
more thorough family history and always consider referring to
a clinical genetics department in such index patients.
 2010 Wiley-Liss, Inc.
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INTRODUCTION
Research into the genetic basis of inherited cardiac disease, includ-
ing cardiomyopathy and familial arrhythmia, and the increased
awareness by patients and physicians of their frequent familial
origin mean that cardiologists are often confronted with families
instead of individual patients [Guttmacher et al., 2004; Charron,
2006; Robin et al., 2007; Cowan et al., 2008; van Spaendonck-Zwarts
et al., 2008; Hershberger et al., 2009a].
Idiopathic dilated cardiomyopathy (DCM) and long QT syn-
drome (LQTS) are increasingly recognized inherited cardiac dis-
eases. DCM is a disease of the myocardium associated with dilation
and impaired contraction of the left or both ventricles. It is familial
in at least 30% of cases, with an autosomal dominant mode of
inheritance being the most common form [Mestroni et al., 1994,
1999; Gr€unig et al., 1998; Crispell et al., 2002; Burkett and Hersch-
berger, 2005; K€arkk€ainen and Peuhkurinen, 2007]. Inherited LQTS
is a genetic channelopathy with reduced penetrance that is associ-
ated with an increased propensity for ventricular tachyarrhythmias
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and sudden cardiac death in young individuals with normal cardiac
morphology. LQTS also generally follows an autosomal dominant
pattern of inheritance [Kahn, 2002; Modell and Lehmann, 2006;
Goldenberg et al., 2008].
Because of the potential familial character and underlying ge-
netic cause and the potential clinical consequences for family
members, obtaining a thorough family history is of great impor-
tance [Guttmacher et al., 2004; Morales et al., 2008]. A positive
family history enables rapid identification of other affected family
members or ones who are at risk for the disease. Early recognition
facilitates prevention through early treatment [Hunt et al., 2003;
Guttmacher et al., 2004; Cowan et al., 2008; Morales et al., 2008;
Hershberger et al., 2009b], especially when sudden cardiac death
at a relatively young age can be the initial manifestation
[Arnestad et al., 2007; Noseworthy and Newton-Cheh, 2008].
A three-generation family history can help establish a diagnosis in
a patient in whom the diagnosis is not completely evident, for
example, because of clinical variability and age-related or reduced
penetrance, which are not unusual in cardiomyopathies and
arrhythmia syndromes like DCM and LQTS [Hunt et al., 2003;
Charron, 2006]. A positive family history is important in making
decisions about more aggressive treatment of affected family mem-
bers such as ICD-implantation [Etheridge et al., 2007; Pasotti
et al., 2008]. A positive family history for sudden death is also an
independent criteria for diagnosing a genetic cardiac disease,
for example, arrhythmogenic right ventricular cardiomyopathy
(ARVC) [McKenna et al., 1994; Calkins and Marcus, 2008;
Hershberger et al., 2009a]. Finally, the family history can provide
information on potential genotype–phenotype correlation if
the disease-causing gene defect has been identified. Conversely,
knowledge of the presentation and development of the cardiac
disease in different family members may facilitate research of
causative genes [Priori et al., 2003; Goldenberg et al., 2008; Morales
et al., 2008].
Despite its demonstrated utility, the accuracy of the family
history taken by cardiologists has not been well studied
[Guttmacher et al., 2004; Gravely-Witte et al., 2008; Hinton,
2008; Morales et al., 2008]. Little is known about the ability of
cardiologists to take a family history and there is no information on
what actions cardiologists undertake if they suspect a patient’s
cardiac disease to have a genetic origin. This means there is
little information on how many diagnoses of inherited cardiac
diseases are missed. We aimed to assess whether cardiologists
in different types of hospitals (a University Medical Center vs. a
General Hospital) have a different approach to taking a family




Patients, aged 18 years or older who were diagnosed with idiopathic
DCM or LQTS between 1996 and 2005 were included. They were
diagnosed in either a university medical center (UMC) or a general
hospital (GH) in the city of Groningen, the Netherlands. 1996 was
selected as the beginning of the study because of the growing
knowledge of DCM and LQTS and the identification of some of
the genes related to these disorders since 1996 [Van Spaendonck-
Zwarts et al., 2008]. Inclusion up to 2005 provided a reasonable
mean follow-up period. Only index patients (the first individual
of the family diagnosed) were included. Patients for whom no
information on follow-up was available were excluded.
Recorded Data
In both hospitals, patients with DCM or LQTS were identified using
diagnosis-related databases. After verifying the diagnosis and its
date, all the relevant information from the medical files was
recorded in a separate database. This information was divided
into: (1) data concerning the family history actually recorded, and
(2) the follow-up assessments after the diagnosis of a potential
hereditary cardiac disease. To ensure this information had been
recorded accurately in the independent database, 10% of the
medical files were randomized and checked by a blinded researcher
(J.P. van Tintelen).
Family History
Analyzed was if a family history was recorded, the degree to which
it was obtained (up to third degree) and the various family
relationships.
Consequences/Follow-Up
Each medical file was examined for the period of cardiological
follow-up in months and if a positive family history was detected,
the subsequent actions were noted. We looked at whether infor-
mation was discussed with the patient, for example, that the
diagnosed (cardiac) disease could be genetic, the possibility of
future cardiologic examination and referral to a clinical genetics
department. We also looked at whether family members had in fact
been examined by a cardiologist, whether DNA analysis had been
initiated and whether the patient had indeed been referred to a
clinical genetics department.
Data Analysis
Discrete variables were compared using the Fisher’s exact test and
are presented as numbers and percentages. Differences between
proportions were tested with a 95% confidence interval (CI)
[Newcombe and Altman, 2005]. The clinical relevance of the
difference between proportions was estimated with Cohen’s effect
size ‘‘h.’’ Effect sizes (ES) were calculated only for the statistically
significant results, since differences between groups that were due to
random variation have no clinical relevance.
Thresholds of effect size ‘‘h’’ for classifying the magnitude of
the differences were: trivial difference (<0.20), small difference
(0.20–<0.50), medium difference (0.50–<0.80), and large
difference (0.80) [Cohen, 1988]. Continuous variables
were compared with the Student’s t-test for independent samples
and are presented as means SD. Statistical analyses were per-
formed using SPSS 12.0.1. for Windows (SPSS, Inc., Chicago, IL).
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RESULTS
Population
In the UMC and the GH, 188 and 138 patients with DCM were
registered, respectively. Fifty and 37 (both 27%) met the criteria for
idiopathic DCM, respectively [Mestroni et al., 1999]. Two medical
files were not available in the UMC and three in the GH, so that the
study population consisted of 48 UMC patients and 34 GH patients
(Fig. 1). In the GH no patients with LQTS were registered. In the
UMC 162 LQTS patients were registered, 140 of whom were
excluded because they were not index patients; they had been
referred because of a positive family history. This left 22 patients
(14%) (Fig. 1), but two files were missing so the final LQTS
population consisted of 20 patients (Fig. 1). The randomized check
of 10% of the medical files found no disagreements in the data
recorded for our study.
The mean age of diagnosis in the DCM population was 44.2 years
in the UMC and 59.0 years in the GH (P< 0.01). The age of
diagnosis in DCM subjects in the UMC was statistically significant
higher than in the LQTS sample (44.2 vs. 30.3 years; P< 0.01).
Family History
A family history was recorded in the medical files of 90% of all LQTS
index patients and 90% of all DCM index patients in the UMC. In
the GH a family history was taken in 82% of DCM patients (Fig. 1).
No significant difference was found between DCM and LQTS
patients with regard to the degree the family history was taken; in
the UMC the degree to which a family history was taken was
recorded for 58% of DCM and for 72% of LQTS patients (ns). In
half of these cases, the family history was restricted to first-degree
family members. In the GH, the degree to which the family history
was taken was recorded for 50% of the DCM patients; in all cases this
was restricted to first-degree family members.
Consequences/Follow-Up
DCM versus LQTS in UMC. In the UMC the mean period of
follow-up was 60 months (range: 11–112 months) after the first
cardiology consultation for the DCM population, and 54 months
(range: 11–107 months) for the LQTS group. This difference was
due to random variation (ns) (Table I).
Significantly higher prevalences were measured in the LQTS
group compared to the DCM group in the UMC for explaining
that the cardiac disease could be genetic, discussing the consequen-
ces for family members, discussing referral, cardiologic examina-
tion of family members, initiating DNA analysis and referral to a
clinical genetics department. The differences between LQTS and
DCM for ‘‘discussing inheritance, discussing the consequences
for the family, cardiologic examination of family members, and
referral’’ were moderate in size, whilst the differences for discussing
referral and initiating DNA analysis were small.
DCM in UMC versus GH. Our final groups of patients were
small (48 UMC vs. 34 GH patients), however we observed that ten of
48 (21%) DCM patients in the UMC were told the cardiac disease
could be genetic compared to 2 of 34 (6%) in the GH (P< 0.05). The
difference was statistically significant (95% CI 0.01–0.28) but small,
according to Cohen’s threshold [1988]. In two UMC DCM cases
(4%) DNA analysis was initiated by the cardiologist compared to
0% for the GH patients (ns). Twelve of 48 (25%) UMC DCM
patients were actually referred to a clinical genetics department
compared to 2 of 34 (6%) of GH patients (P< 0.05). This difference
FIG. 1. Subjects: DCM versus LQTS index patients. D, mean age of diagnosis in years; f, female; GH, General Hospital; (i)DCM, dilated cardiomyopathy,
idiopathic; LQTS, Long QT syndrome; m, male; UMC: University Medical Center.
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was statistically significant but also classified as small. Other differ-
ences for DCM index patients in the UMC and GH were not
significant (Table II).
DISCUSSION
One of the most effective measures of a person’s risk for a genetic
disease is analysis of the family history [Frezzo et al., 2003; Nasir
et al., 2007], especially for autosomal dominant cardiac diseases like
DCM and LQTS. In addition to helping recognize genetic cardiac
disease in the patient, it can help in the early identification of
other family members at risk for developing such disease, thereby
enabling secondary and tertiary prevention [Hunt et al., 2003;
Guttmacher et al., 2004; Cowan et al., 2008; Morales et al., 2008;
Hershberger et al., 2009b].
Study Population
In LQTS, symptoms (like dizziness, fainting, and palpitations)
appear on average between 9 and 16 years of age [Zareba et al.,
2003; Goldenberg et al., 2008], whereas symptoms in DCM (like
fatigue, shortness of breath) start on average after 30–35 years
of age [Mestroni et al., 1999; Burkett and Herschberger, 2005;
Hershberger et al., 2009a]. This difference is reflected in the age of
diagnosis in our patient groups.
Family History
Regarding the degree to which the family history taken by the
participating cardiologists in the UMC, we saw no differences
between the DCM and LQTS index patients. However, for the
DCM index patients, cardiologists in the UMC were often more
specific in how they took a family history compared to how this was
done in the GH. In all cases the family history taken in the GH was
restricted to first-degree family members. A family history restrict-
ed to first-degree family members can easily result in missing the
diagnosis of genetic cardiac disease because of the clinical variability
and age-related or reduced penetrance seen in DCM and LQTS
[Crispell et al., 2002; Charron, 2006]. A family history well beyond
first-degree members and at least three generations is therefore of
TABLE II. Comparison of Cardiologists in the University Medical Center and General Hospital in Their Approach to DCM Index Patients
UMCG, N¼ 48 GH, N¼ 34
Difference of proportions test, 95% CIa
Effect size
Follow-up in months (SD) 59.8 (28.93) 51.2 (23.98)b n.s.
Family history (%) 43 (90%) 28 (82%) 8.2 22.7 0.21
Discussion
Inheritance 10 (21%) 2 (6%) 0.01 0.28 n.s.
Consequences for family 3 (6%) 1 (3%) 5.6 12.2 n.s.
Referral clinical genetics 6 (13%) 1 (3%) 1.4 20.0 n.s.
Cardiologic examination family 4 (8%) 1 (3%) 4.3 15.1 n.s.
DNA analysis 2 (4%) 0 (0%) 1.5 9.8 n.s.
Referral clinical genetics 12 (25%) 2 (6%) 4.5 33.7 0.25
CI, confidence interval; n.s., not significant.
aNewcombe and Altman [2005].
bStudent’s t-test for independent samples.
TABLE I. Comparison of LQTS and DCM Index Patients in the UMC
LQTS, N¼ 20 DCM, N¼ 48
Difference of proportions test, 95% CIa
Effect size
Follow-up in months (SD) 53.6 (29.47) 59.8 (28.93)b n.s.
Family history (%) 18 (90%) 43 (90%) n.s.
Discussion:
Inheritance 15 (75%) 10 (21%) 0.32 0.76 0.51
Consequences for family 11 (55%) 3 (6%) 0.26 0.48 0.55
Referral clinical genetics 8 (40%) 6 (13%) 0.04 0.51 0.31
Cardiologic examination family 12 (60%) 4 (8%) 0.29 0.74 0.55
DNA analysis 7 (35%) 2 (4%) 0.09 0.52 0.41
Referral clinical genetics 16 (80%) 12 (25%) 0.33 0.76 0.51
CI, confidence interval; n.s., not significant.
aNewcombe and Altman [2005].
bStudent’s t-test for independent samples.
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great importance and has recently also been recommended by the
Heart Failure Society of America [Hershberger et al., 2009b].
Consequences/Follow-Up
Perhaps the most important finding was that cardiologists took
significantly more often action if they diagnosed LQTS compared to
DCM. In particular, cardiologic examination was offered more
often to first-degree family members of LQTS index patients than to
those of DCM index patients (60% vs. 8%, P¼ 0.00). LQTS patients
were also significantly more often referred to a clinical genetics
department than DCM patients (80% vs. 25%, P< 0.01) (Table I).
It seems cardiologists make more effort to identify family
members at risk for LQTS, probably because the genetic knowledge
of LQTS is more advanced than for DCM, there is a high risk of
sudden death as a first manifestation of LQTS [Arnestad et al.,
2007], and LQTS is more likely to have a genetic origin [Goldenberg
et al., 2008]. Genetic testing for LQTS has clear benefits for the
patient as well as their family members. This is mainly because the
choice of therapy largely depends on the genetic subtype. Besides,
because of the non-penetrance of ECG characteristics, genetic
testing is necessary to identify family members at risk. Subsequent
treatment may prevent sudden death [Priori et al., 2003; Golden-
berg et al., 2008; Gimeno et al., 2009]. For LQTS genetic testing has
been shown to be cost-effective relative to no testing [Phillips et al.,
2005].
In DCM the benefit of genetic testing is less clear, because
treatment is not dependent on genotype. A possible exception is
that carriers of a mutation in the gene encoding lamin A and C
(LMNA) are believed to be at high risk for sudden cardiac death,
justifying ICD-implantation [Meune et al., 2006; van Tintelen et al.,
2007; Pasotti et al., 2008]. Sudden death can therefore be a first, yet
rare, manifestation of DCM [Noseworthy and Newton-Cheh,
2008]. Despite the fact that DCM has many underlying causes
such as myocarditis, coronary disease, alcohol intoxication, or
chemotherapy, at least 30% of DCM cases are familial [Mestroni
et al., 1999; K€arkk€ainen and Peuhkurinen, 2007; Hershberger et al.,
2009a]. Cascade genetic testing for DCM will facilitate the recog-
nition of those family members who can be dismissed from regular
follow-up screening. Thus, cardiologists must be as attentive in
identifying at-risk family members with DCM as compared to
LQTS.
Cardiologists in the UMC referred DCM patients to the clinical
genetics department significantly more often than those in the GH
(25% vs. 6%). This may be due to the cardiogenetic clinic’s setting in
the UMC, where cardiologists and clinical geneticists regularly
consult each other and meet for research purposes. Cardiologists
in a UMC may have more knowledge about the inheritance of DCM
and LQTS, and the usefulness of DNA analysis in risk stratification.
CONCLUSION
Although a family history is generally taken by cardiologists, this
study shows that follow-up actions (screening of family-members/
referral) were performed significantly more often for LQTS than
DCM index patients. Cardiologists thus take significantly more
effort to identify family members at risk for LQTS in comparison to
DCM. One-third of DCM and nearly all LQTS cases are familial, in
which sudden death can be a first manifestation and timely treat-
ment is essential. We recommend that cardiologists take a more
thorough family history and always consider referral to a clinical
genetics department or cardiogenetics clinics to identify family
members at risk.
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